Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 61, Issue 1-2, 1997, Pages 97-106

  Dodge, Jeffrey A ^a   Lugar, Charles W ^a   Cho, Stephen ^a   Short, Lorri L ^a   Sato, Masahiko ^a   Yang, Na N ^a   Spangle, Larry A ^a   Martin, Michael J ^a   Phillips, David L ^a   Glasebrook, Andrew L ^a   Osborne, John J ^a   Frolik, Charles A ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ESTROGEN RECEPTOR; RALOXIFENE; RALOXIFENE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOCLAST; OSTEOLYSIS; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; BONE RESORPTION; BREAST NEOPLASMS; CELL DIVISION; CELLS, CULTURED; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GLUCURONATES; HUMANS; INTERLEUKIN-6; ORGAN SPECIFICITY; OSTEOCLASTS; OVARIECTOMY; PIPERIDINES; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 17544404426     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00008-3     Document Type: Article

References (30)

1. Lindsay, R., Sex steroids in the pathogenesis and prevention of osteoporosis. In Osteoporosis: Etiology, Diagnosis, and Management, eds B. L. Riggs and L. J. Menton. Raven, New York, 1988, pp. 333-358.
2. Ross, R. K., Pike, M. C., Mack, T. M. and Henderson, B. E., Oestrogen replacement therapy and cardiovascular disease. In HRT and Osteoporosis, eds J. O. Drife and J. W. W. Studd. Springer-Verlag, London, 1990, pp. 209-222.
3. Henderson V. W., Paganini-Hill A., Emanuel C. K., Dunn M. E. and Buckwalter J. G., Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch. Neurol. 51 (1994) 896.
4. Felson D. T., Zhang Y., Hannan M. T., Kiel D. P., Wilson P. W. F. and Anderson J. J., The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med, 329 (1993) 1141-1146.
5. Stampfer M. J., Colditz G. A., Willet W. C., Manson J. E., Rosner B., Speizer F. E. and Hennekens C. H., Postmenopausal estrogen replacement therapy and cardiovascular disease: ten-year follow up from the nurse's health study. N. Engl. J. Med. 325 (1991) 756-762.
6. Ziel H. K. and Finkle W. D., Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med. 293 (1975) 1167-1170.
7. Smith D. C., Prentice R., Thompson D. J. and Herrmann W. L., Association of erogenous estrogen and endometrial cancer. N. Engl. J. Med. 293 (1975) 1164-1167.
8. Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Mansen J. E., Stampfer M. J., Hennekens C., Rosner B. and Speizer F. E., The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332 (1995) 1589-1593.
9. Jones C. D., Jevnikar M. G., Pike A. J., Peters M. K., Black L. J., Thompson A. R., Falcone J. F. and Clemens J. A., Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thlophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thienyl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27 (1984) 1057-1066.
10. Draper M. W., Flowers D. E., Huster W. J., Neild J. A., Harper J. E. and Arnaud C., A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Min. Res. 11 (1996) 835-842.
11. Sato M., Bryant H. U., Iverson P., Helterbrand J., Smietana E., Bemis K., Higgs R., Turner C. H., Owan I., Takano Y. Burr D. B., Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J. Pharmacol. Exp. Ther. 279 (1996) 298-305.
12. Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., Cullinan G. J., Bendele R., Kauffman R. F., Bensch W. R., Frolik C. A., Termine J. D. and Bryant H. U., Raloxifene (LY139478 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 93 (1994) 63-69.
13. Clemens J. A., Bennet D. R., Black L. J. and Jones C. D., Effects if a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and LH and prolactin levels. Life Sci. 32 (1983) 2869-2875.
14. Gottardis M. M. and Jordan V. C., Antitumor actions of keoxifene and tamoxifen in the N-nitromethylurea-induced rat mammary carcinoma model. Cancer Res. 47 (1987) 4020-4024.
15. Kauffman R. F. and Bryant H. U., Selective estrogen receptor modulators. Drug News Perspect. 8 (1995) 531-539.
16. Evans G. L. and Turner R. T., Tissue-selective actions of estrogen analogs. Bone 17 (1995) 181S-190S.
17. Grese, T. A. and Dodge, J. A., Estrogen receptor modulators: effects in non-traditional target tissues. In Annual Reports in Medicinal Chemistry, Vol. 31, ed. J. A. Bristol. Academic Press, New York, 1996, pp. 181-190.
18. Katzenellenbogen J. A., O'Malley B. W. and Katzenellenbogen B. S., Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Molec. Endocr. 10 (1996) 119-131.
19. McDonnell D. P., Clemm D. L., Hermann T., Goldman M. E. and Pike J. W., Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molec. Endocr. 9 (1995) 659-669.
20. Lindstrom T. D., Whitaker N. G. and Whitaker G. W., Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs, and monkeys. Xenobiotica 11 (1984) 841-847.
21. Forgue S. T., Rudy A. C., Knadler M. P., Basson R. P., Nelson J. E., Henry D. P. and Allerheiligen S. R., Raloxifene pharmacokinetics in healthy postmenopausal women. Pharmaceut. Res. 13 (1996) 429.
22. Ni L., Allerheiligen S. R., Basson R., Knadler M. P., Latz J., Geiser J, Lantz R., Rash J. and Henry D. P., Pharmacokinetics of raloxifene in men and postmenopausal women volunteers. Pharmaceut. Res. 13 (1996) 430.
23. Allerheiligen S., Geiser J., Knadler M. P., Basson R., Miller J., Lantz L., Rash J. and Draper M., Raloxifene (RAL) pharmacokinetics and the associated endocrine effects in premenopausal women treated during the follicular, ovulatory, and luteal phases of the menstrual cycle. Pharmaceut. Res. 13 (1996) S430.
24. 2 as catalyst. Tetrahedron Lett. 34 (1993) 4531-4534.
25. Bollenback G. N., Long J. W., Benjamin D. G. and Lindquist J. A., The synthesis of aryl-D-glucopyranosiduronic acids. J. Am. Chem. Soc. 77 (1955) 3310-3315.
26. 3H-isotopomer of raloxifene. J. Label. Compounds Radiopharmaceut. 36 (1995) 43-49.
27. 3) gene expression in rat bone: a potential mechanism for estrogen and raloxifene mediated bone maintenance. Endocrinology 137 (1996) 2074-2084.
28. Thompson E. W., Katz D., Shima T. B.:, Wakeling A. E., Lippman M. E. and Dickson R. B., ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation. Cancer Res. 49 (1989) 6929-6934.
29. Katzenellenbogen B. S., Kendra K. L., Norman M. J. and Berthois Y., Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer. Res. 47 (1987) 4355-4360.
30. Sato, M. and Bryant, H. U., Raloxifene efficacy in nonreproductive and reproductive tissues in rat models in vivo and in vitro. In In vitro Biology of Sex Steroid Hormone Action, eds H. Kuramoto and E. Gurpide. Churchill Livingstone, Tokyo, 1996, pp. 406-421.